Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545270 | 0.86 | BRAF (0.52) | BRAFKDRRAF1 | |
| SCHEMBL545191 | 0.86 | BRAF (0.52) | BRAFKDRRAF1 | |
| SCHEMBL546193 | 0.86 | BRAF (0.52) | BRAFKDRRAF1 | |
| SCHEMBL544984 | 0.83 | BRAF (0.43) | BRAFKDRRAF1 | |
| SCHEMBL545087 | 0.82 | BRAF (0.43) | BRAFKDRRAF1 | |
| SCHEMBL545697 | 0.79 | BRAF (0.58) | BRAFKDRRAF1 | |
| SCHEMBL545404 | 0.76 | BRAF (0.49) | BRAFKDRRAF1 | |
| SCHEMBL3546037 | 0.76 | RAF1 (0.47) | BRAFKDRLMNARAF1 | |
| SCHEMBL545338 | 0.75 | BRAF (0.49) | BRAFKDRRAF1 | |
| SCHEMBL545645 | 0.74 | BRAF (0.48) | BRAFKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | TP53 1008/4885MAPT 2178/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.